15.7000.51% ( -0.080 )
Delay Closed: Nov 17, 16:08:15Valuation
Current ValuationThe current P/E ratio is 28.23, above the reasonable range, cheaper than 6.52% of the time in the past 5 years, and the industry ranks 18/78, the industry Median -4.90.
28.23xP/E
HK$15.70Stock price
HK$0.56Earnings per share
28.23xP/E
Stock priceHK$15.70Earnings per shareHK$0.56
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 16.04x
- Typical range
- 14.03x–21.48x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0150300450600
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
02696HKHENLIUS | 23.96x | 25.47% | HK$23.93B |
02162HKKEYMED BIO-B | 22.92x | 248.55% | HK$20.42B |
02157HKLEPU BIO | 16.56x | 127.52% | HK$4.71B |
06826HKHAOHAI BIOTEC | 28.23x | 128.83% | HK$3.59B |
02181HKMABPHARM-B | 20.71x | -- | HK$2.04B |
06915HKJIANGXI BIO | 19.44x | -- | HK$1.62B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
